{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T06:51:19Z","timestamp":1773557479645,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With a growing aging population, the prevalence of age-related eye disease and associated eye care is expected to increase. The anticipated growth in demand, coupled with recent medical advances that have transformed eye care for people living with retinal diseases, particularly neovascular age-related macular degeneration (nAMD) and diabetic eye disease, has presented an opportunity for health systems to proactively manage the expected burden of these diseases. To do so, we must take collective action to address existing and anticipated capacity limitations by designing and implementing sustainable strategies that enable health systems to provide an optimal standard of care. Sufficient capacity will enable us to streamline and personalize the patient experience, reduce treatment burden, enable more equitable access to care and ensure optimal health outcomes. Through a multi-modal approach that gathered unbiased perspectives from clinical experts and patient advocates from eight high-income countries, substantiated perspectives with evidence from the published literature and validated findings with the broader eye care community, we have exposed capacity challenges that are motivating the community to take action and advocate for change. Herein, we propose a collective call-to-action for the future management of retinal diseases and potential strategies to achieve better health outcomes for individuals at-risk of, or living with, retinal disease.<\/jats:p>","DOI":"10.1038\/s41433-023-02540-w","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T17:06:40Z","timestamp":1686071200000},"page":"3351-3359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avril","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-8143","authenticated-orcid":false,"given":"Javier","family":"Zarranz-Ventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-4356","authenticated-orcid":false,"given":"Robyn","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"2540_CR1","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9:e489\u2013e551.","journal-title":"Lancet Glob Health"},{"key":"2540_CR2","unstructured":"World Health Organization. Blindness and vision impairment. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment. Accessed 30 November 2022."},{"key":"2540_CR3","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.eclinm.2021.100852","volume":"35","author":"AP Marques","year":"2021","unstructured":"Marques AP, Ramke J, Cairns J, Butt T, Zhang JH, Muirhead D, et al. Global economic productivity losses from vision impairment and blindness. EClinicalMedicine. 2021;35:100852.","journal-title":"EClinicalMedicine"},{"key":"2540_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-2836-0","volume":"18","author":"L Pezzullo","year":"2018","unstructured":"Pezzullo L, Streatfeild J, Simkiss P, Shickle D. The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018;18:63.","journal-title":"BMC Health Serv Res"},{"key":"2540_CR5","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u2013116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"2540_CR6","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pr. 2019;157:107843.","journal-title":"Diabetes Res Clin Pr"},{"key":"2540_CR7","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128:1580\u201391.","journal-title":"Ophthalmology"},{"key":"2540_CR8","unstructured":"Global Coalition on Aging. 2020 International Vision Scorecard. 2020. https:\/\/globalcoalitiononaging.com\/wp-content\/uploads\/2020\/11\/GCOA-Vision-Scorecard_11.18.20.pdf. Accessed 4 February 2022."},{"key":"2540_CR9","unstructured":"The Royal College of Ophthalmologists. The Way Forward: Options to help meet demand for the current and future care of patients with eye disease. 2016. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/12\/RCOphth-The-Way-Forward-AMD-300117.pdf. Accessed 4 February 2022."},{"key":"2540_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20:294.","journal-title":"BMC Ophthalmol"},{"key":"2540_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mones","year":"2020","unstructured":"Mones J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243:1\u20138.","journal-title":"Ophthalmologica"},{"key":"2540_CR12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/OPTH.S92548","volume":"9","author":"M Varano","year":"2015","unstructured":"Varano M, Eter N, Winyard S, Wittrup-Jensen KU, Navarro R, Heraghty J. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. Clin Ophthalmol. 2015;9:2243\u201350. https:\/\/doi.org\/10.2147\/OPTH.S92548","journal-title":"Clin Ophthalmol"},{"key":"2540_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1370\/afm.857","volume":"6","author":"TF Farley","year":"2008","unstructured":"Farley TF, Mandava N, Prall FR, Carsky C. Accuracy of primary care clinicians in screening for diabetic retinopathy using single-image retinal photography. Ann Fam Med. 2008;6:428\u201334.","journal-title":"Ann Fam Med"},{"key":"2540_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/imj.14309","volume":"49","author":"S Atkinson-Briggs","year":"2019","unstructured":"Atkinson-Briggs S, Jenkins A, Keech A, Ryan C, Brazionis L. Integrating diabetic retinopathy screening within diabetes education services in Australia\u2019s diabetes and indigenous primary care clinics. Intern Med J. 2019;49:797\u2013800.","journal-title":"Intern Med J"},{"key":"2540_CR15","doi-asserted-by":"publisher","first-page":"946915","DOI":"10.3389\/fendo.2022.946915","volume":"13","author":"X Huang","year":"2022","unstructured":"Huang X, Wang H, She C, Feng J, Liu X, Hu X, et al. Artificial intelligence promotes the diagnosis and screening of diabetic retinopathy. Front Endocrinol. 2022;13:946915.","journal-title":"Front Endocrinol"},{"key":"2540_CR16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2016.17216","volume":"316","author":"V Gulshan","year":"2016","unstructured":"Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316:2402\u201310.","journal-title":"JAMA"},{"key":"2540_CR17","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1001\/jama.2017.18152","volume":"318","author":"DSW Ting","year":"2017","unstructured":"Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA. 2017;318:2211\u201323.","journal-title":"JAMA"},{"key":"2540_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41433-019-0566-0","volume":"34","author":"A Grzybowski","year":"2020","unstructured":"Grzybowski A, Brona P, Lim G, Ruamviboonsuk P, Tan GSW, Abramoff M, et al. Artificial intelligence for diabetic retinopathy screening: a review. Eye. 2020;34:451\u201360.","journal-title":"Eye"},{"key":"2540_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00592-021-01687-w","volume":"58","author":"PH Scanlon","year":"2021","unstructured":"Scanlon PH. The contribution of the English NHS Diabetic Eye Screening Programme to reductions in diabetes-related blindness, comparisons within Europe, and future challenges. Acta Diabetol. 2021;58:521\u201330.","journal-title":"Acta Diabetol"},{"key":"2540_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0318-x","volume":"16","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, de la Riva-Fernandez S, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N, et al. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. BMC Ophthalmol. 2016;16:136.","journal-title":"BMC Ophthalmol"},{"key":"2540_CR21","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jcjo.2017.09.022","volume":"52","author":"R Kanjee","year":"2017","unstructured":"Kanjee R, Dookeran RI, Mathen MK, Stockl FA, Leicht R. Six-year prevalence and incidence of diabetic retinopathy and cost-effectiveness of tele-ophthalmology in Manitoba. Can J Ophthalmol. 2017;52:S15\u2013S18.","journal-title":"Can J Ophthalmol"},{"key":"2540_CR22","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.ophtha.2016.08.021","volume":"123","author":"HV Nguyen","year":"2016","unstructured":"Nguyen HV, Tan GS, Tapp RJ, Mital S, Ting DS, Wong HT, et al. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore. Ophthalmology. 2016;123:2571\u201380.","journal-title":"Ophthalmology"},{"key":"2540_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2337\/dc11-0943","volume":"35","author":"CD Jones","year":"2012","unstructured":"Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35:592\u20136.","journal-title":"Diabetes Care"},{"key":"2540_CR24","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.2337\/dc10-2308","volume":"34","author":"E Agardh","year":"2011","unstructured":"Agardh E, Tababat-Khani P. Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care. 2011;34:1318\u20139.","journal-title":"Diabetes Care"},{"key":"2540_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19740","volume":"19","author":"PH Scanlon","year":"2015","unstructured":"Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess. 2015;19:1\u2013116.","journal-title":"Health Technol Assess"},{"key":"2540_CR26","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41433-021-01646-3","volume":"36","author":"R Chopra","year":"2022","unstructured":"Chopra R, Preston GC, Keenan TDL, Mulholland P, Patel PJ, Balaskas K, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye. 2022;36:1373\u20138.","journal-title":"Eye"},{"key":"2540_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ceo.13085","volume":"46","author":"M Ozturk","year":"2017","unstructured":"Ozturk M, Harris ML, Nguyen V, Barthelmes D, Gillies MC, Mehta H. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence. Clin Exp Ophthalmol. 2017;46:407\u201311.","journal-title":"Clin Exp Ophthalmol"},{"key":"2540_CR28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2014","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2014;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"2540_CR29","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","volume":"37","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina. 2017;37:2254\u201361.","journal-title":"Retina"},{"key":"2540_CR30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaophthalmol.2021.3096","volume":"139","author":"T Li","year":"2021","unstructured":"Li T, Sun J, Min J, Zhou S, Zhu X, Jia H, et al. Safety of receiving anti-vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: a meta-analysis. JAMA Ophthalmol. 2021;139:1080\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"2540_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jcjo.2014.03.009","volume":"49","author":"L Xing","year":"2014","unstructured":"Xing L, Dorrepaal SJ, Gale J. Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can J Ophthalmol. 2014;49:261\u20136.","journal-title":"Can J Ophthalmol"},{"key":"2540_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/opo.12217","volume":"35","author":"E Samia-Aly","year":"2015","unstructured":"Samia-Aly E, Cassels-Brown A, Morris DS, Stancliffe R, Somner JE. A survey of UK practice patterns in the delivery of intravitreal injections. Ophthalmic Physiol Opt. 2015;35:450\u20134.","journal-title":"Ophthalmic Physiol Opt"},{"key":"2540_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/aos.12589","volume":"93","author":"PW Hasler","year":"2015","unstructured":"Hasler PW, Bloch SB, Villumsen J, Fuchs J, Lund-Andersen H, Larsen M. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting. Acta Ophthalmol. 2015;93:122\u20135.","journal-title":"Acta Ophthalmol"},{"key":"2540_CR34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.12968\/bjon.2017.26.14.800","volume":"26","author":"M Gallagher","year":"2017","unstructured":"Gallagher M. Introduction of a nurse\u2013led intravitreal injection service in ophthalmology. Br J Nurs. 2017;26:800\u20133.","journal-title":"Br J Nurs"},{"key":"2540_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/aos.14184","volume":"98","author":"S Bolme","year":"2020","unstructured":"Bolme S, Morken TS, Follestad T, Sorensen TL, Austeng D. Task shifting of intraocular injections from physicians to nurses: a randomized single-masked noninferiority study. Acta Ophthalmol. 2020;98:139\u201344.","journal-title":"Acta Ophthalmol"},{"key":"2540_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","volume":"129","author":"NM Holekamp","year":"2022","unstructured":"Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129:295\u2013307.","journal-title":"Ophthalmology"},{"key":"2540_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","volume":"126","author":"PA Campochiaro","year":"2019","unstructured":"Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019;126:1141\u201354.","journal-title":"Ophthalmology"},{"key":"2540_CR38","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41433-019-0479-y","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Parachuri N, Kuppermann BD, Bandello F, Regillo CD. Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression. Eye. 2020;34:422\u20133.","journal-title":"Eye"},{"key":"2540_CR39","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41433-021-01766-w","volume":"36","author":"F Ghanchi","year":"2022","unstructured":"Ghanchi F, Bourne R, Downes SM, Gale R, Rennie C, Tapply I, et al. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. Eye. 2022;36:1154\u201367.","journal-title":"Eye"},{"key":"2540_CR40","first-page":"205","volume":"63","author":"J Cleland","year":"2022","unstructured":"Cleland J, Sharma R, Appiani S, Moore J, Rogers B. Safety and tolerability of a single subcutaneous dose of anti-angiogenesis drug to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Abstracts of the 2022 AVRO Annual Meeting. Investig Ophthalmol Vis Sci. 2022;63:205.","journal-title":"Investig Ophthalmol Vis Sci."},{"key":"2540_CR41","doi-asserted-by":"publisher","unstructured":"Arepalli S, Kaiser PK. Pipeline therapies for neovascular age related macular degeneration. Int J Retina Vitreous. 2021;7. https:\/\/doi.org\/10.1186\/s40942-021-00325-5.","DOI":"10.1186\/s40942-021-00325-5"},{"key":"2540_CR42","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"KL Spooner","year":"2018","unstructured":"Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol. 2018;12:2483\u201391.","journal-title":"Clin Ophthalmol"},{"key":"2540_CR43","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/opo.12836","volume":"41","author":"S Read","year":"2021","unstructured":"Read S, Lawrenson JG, Harper RA, Hanley T, Balaskas K, Waterman H. Evaluation of training, patient and practitioner perspectives on community-based monitoring of patients with stable age-related macular degeneration compared to hospital-based care: The FENETRE study report no. 1. Ophthalmic Physiol Opt. 2021;41:864\u201373.","journal-title":"Ophthalmic Physiol Opt"},{"key":"2540_CR44","first-page":"3810","volume":"54","author":"N Rob","year":"2013","unstructured":"Rob N, North L, Absaru G, Zacharaki F, Chandran M, Menon G. Evaluation of the accuracy and efficiency of an optometrist led stable AMD clinic in a regional Age Related Macular Degeneration (AMD) Centre. Abstracts of the 2013 ARVO Annual Meeting. Investig Ophthalmol Vis Sci. 2013;54:3810.","journal-title":"Investig Ophthalmol Vis Sci."},{"key":"2540_CR45","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/jcm10071355","volume":"10","author":"AC Ho","year":"2021","unstructured":"Ho AC, Heier JS, Holekamp NM, Garfinkel RA, Ladd B, Awh CC, et al. Real-world performance of a self-operated home monitoring system for early detection of neovascular age-related macular degeneration. J Clin Med. 2021;10:1355.","journal-title":"J Clin Med"},{"key":"2540_CR46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jamaophthalmol.2017.0255","volume":"135","author":"JS Wittenborn","year":"2017","unstructured":"Wittenborn JS, Clemons T, Regillo C, Rayess N, Liffmann Kruger D, Rein D. Economic evaluation of a home-based age-related macular degeneration monitoring system. JAMA Ophthalmol. 2017;135:452\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"2540_CR47","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939\u201346.","journal-title":"Clin Ophthalmol"},{"key":"2540_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/20543581221081207","volume":"9","author":"L Dubrofsky","year":"2022","unstructured":"Dubrofsky L, Lee JF, Hajimirzarahimshirazi P, Liu H, Weisman A, Lawler PR, et al. A unique multi- and interdisciplinary cardiology-renal-endocrine clinic: a description and assessment of outcomes. Can J Kidney Health Dis. 2022;9:20543581221081207.","journal-title":"Can J Kidney Health Dis"},{"key":"2540_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2147\/OPTH.S185186","volume":"13","author":"R Annoh","year":"2019","unstructured":"Annoh R, Patel S, Beck D, Ellis H, Dhillon B, Sanders R. Digital ophthalmology in Scotland: benefits to patient care and education. Clin Ophthalmol. 2019;13:277\u201386.","journal-title":"Clin Ophthalmol"},{"key":"2540_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.puhe.2014.10.010","volume":"129","author":"AA Khan","year":"2015","unstructured":"Khan AA, Mustafa MZ, Sanders R.Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication.Scotland. Public Health.2015;129:117\u201323.","journal-title":"Scotland. Public Health."},{"key":"2540_CR51","unstructured":"The Apperta Foundation CIC. Scottish National Eyecare Service adopts OpenEyes. 2020. https:\/\/openeyes.apperta.org\/news\/2020\/12\/16\/scottish-national-eyecare-service-adopts-openeyes.html. Accessed 15 December 2022."},{"key":"2540_CR52","unstructured":"NHS South Tees Hospitals NHS Foundation Trust. Emergency eye clinic referral guidance. 2021. https:\/\/www.southtees.nhs.uk\/content\/uploads\/2021\/11\/Emergency-eye-clinic-fast-track-clinic-referral-pathway-protocol.pdf. Accessed 1 March 2023."},{"key":"2540_CR53","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/eye.2011.343","volume":"26","author":"W Amoaku","year":"2012","unstructured":"Amoaku W, Blakeney S, Freeman M, Gale R, Johnston R, Kelly SP, et al. Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Eye. 2012;26:S2\u201321.","journal-title":"Eye"},{"key":"2540_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40123-017-0091-9","volume":"6","author":"Y Yang","year":"2017","unstructured":"Yang Y, Downey L, Mehta H, Mushtaq B, Narendran N, Patel N, et al. Resource use and real-world outcomes for ranibizumab treat and extend for neovascular age-related macular degeneration in the UK: interim results from TERRA. Ophthalmol Ther. 2017;6:175\u201386.","journal-title":"Ophthalmol Ther"}],"updated-by":[{"DOI":"10.1038\/s41433-023-02662-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000}}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02540-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02540-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02540-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T10:06:58Z","timestamp":1699351618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02540-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":54,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2540"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02540-w","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41433-023-02662-1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41433-023-02662-1","URL":"https:\/\/doi.org\/10.1038\/s41433-023-02662-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AL has consulted for Roche, Notal Vision, Bayer, Novartis, and Abbvie. RGu consults with Roche, Genentech, Apellis, Bayer, Novartis, and Janssen Research & Development. RGa has received institutional research grants funded by Bayer, Novartis, and Roche and has consulted for Apellis, Allergan, Biogen, Bayer, Novartis, Roche. AD does not have any direct competing interests to disclose; however, Retina International (where Avril serves as CEO) receives unrestricted educational grants from, F. Hoffman LaRoche, Novartis, Apellis, and Janssen. FR and JZ-V are members of the <i>Eye<\/i> editorial board. AB and CC-G declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}